Serina Therapeutics, Inc. (SER)

The FDA placed a clinical hold on the IND application for SER-252, and Serina Therapeutics submitted a complete response. The company reported a net loss of $6.4 million in Q3 2025. Dr. Joshua Thomas was appointed as VP, Head of Chemistry. Chief Scientific Officer Randall Moreadith engaged in multiple stock sales. Serina Therapeutics' stock price has experienced a significant decline of approximately 54.02% over the past six months.

There is no specific information available regarding demand seasonality for Serina Therapeutics, Inc.'s products or services. Demand for its products, once approved, would primarily be driven by disease prevalence, treatment efficacy, and market adoption rather than typical seasonal fluctuations. The company's revenue is currently low, reflecting its clinical-stage status.

Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and pain, operating within the Healthcare sector. Their core technology, the POZ Platform™, optimizes drug delivery. Key product candidates include SER 252 for Parkinson's disease, SER 214 for early Parkinson's and Restless Leg Syndrome, SER 270 for Tardive Dyskinesia, and POZ-lipids as an alternative to PEG-lipids. The company also explores POZ technology in RNA vaccines.

Serina Therapeutics, Inc. is headquartered in Huntsville, Alabama, United States, on the campus of the HudsonAlpha Institute of Biotechnology.

Serina Therapeutics' brand reputation has been influenced by positive developments and regulatory challenges. Positive FDA feedback and funding for SER-252, along with the appointment of Dr. Joshua Thomas, contributed positively. The FDA's clinical hold on SER-252 and reported net losses had a temporary negative impact. The company's response to the FDA and commitment to regulatory compliance demonstrate its dedication to advancing its pipeline.

Serina Therapeutics has a mixed ownership structure. Major institutional owners include Vanguard Group Inc and BlackRock Inc, holding a total of 477,956 shares. Major individual and insider owners include Juvenescence Ltd, Steven A. Ledger (CEO), and John F. Mauldin. Insiders collectively own approximately 60.21% of the company's stock.